The answer so far
Two human reports investigated Semax at different stages after ischemic stroke, but the abstracts available here do not establish a reliable causal treatment benefit. If stroke symptoms may be happening now, call local emergency services immediately—even if the symptoms go away.1256
On this page
If stroke symptoms are happening now
A stroke is an emergency. Sudden face drooping, weakness in an arm or leg, trouble speaking, sudden vision or balance problems, or a sudden severe headache can be warning signs. Call your local emergency number immediately, even if symptoms disappear: 911 in the US, 999 in the UK, or 112 in the EU. Tell the dispatcher when symptoms began if known, and follow their instructions. Do not wait to try a product or drive yourself. The individual signs have other possible causes, but need urgent assessment.567
Why is Semax discussed after stroke?
Semax is a synthetic peptide studied in several contexts, including reports involving people after an ischemic stroke. An ischemic stroke occurs when blood flow to part of the brain is blocked; a stroke can also result from bleeding. Treatment depends on the type and individual situation. Interest in a peptide as an additional treatment is a research question, not a reason to delay emergency care or change a recovery plan. For background, start with the Semax profile.15
What did the 1997 acute-stroke report say?
The English abstract describes 30 people who received Semax during the acute phase of ischemic stroke and 80 comparison patients treated with conventional care. The authors reported improvement in neurological measures, particularly movement. The abstract does not explain enough about allocation, blinding or numerical results to determine how much improvement was caused by Semax. We reviewed the English abstract, not the full Russian-language paper. This is a human report with a comparison, but it does not establish a reliable treatment effect on its own.1
What did the later rehabilitation report study?
A 2018 English abstract describes 110 people after ischemic stroke, divided into earlier and later rehabilitation groups, with Semax and no-Semax subgroups. The reported average times after stroke were roughly three months and seven months. Researchers assessed movement, a daily-activity measure called the Barthel index, and a blood marker called BDNF. The authors reported more favourable recovery patterns with Semax, but the abstract does not give enough detail about group assignment, blinding, subgroup sizes or numerical between-group results to establish causation. We reviewed the abstract, not the full paper. Its 110 people are not automatically the same as, or additional to, the people in the 1997 report.2
- 1997: acute strokeThe abstract describes 30 people given Semax and 80 receiving conventional care.
- 2018: rehabilitationThe abstract describes 110 people in earlier or later rehabilitation, with Semax and no-Semax subgroups.
- What was measured?The reports discuss neurological signs, daily activities, movement and a blood marker.
- What remains uncertain?The abstracts do not give enough detail to establish how much change was caused by Semax.
Does higher BDNF prove recovery?
BDNF is a protein involved in the growth and function of nerve cells. Its level in a blood sample is a biological marker, not a direct measure of a person’s independence or proof that a product repaired brain tissue. The Barthel index asks about activities such as everyday self-care; movement scores assess another part of recovery. Those outcomes matter, but differences between groups can have several explanations, including rehabilitation timing and the people selected, when study methods are unclear.2
What did the FDA evaluate?
In its July 2026 US compounding briefing, FDA listed the Russian-language stroke reports but said it did not consider them in its effectiveness evaluation because verified English translations were not available. For the information it did evaluate, FDA concluded that evidence was insufficient to support Semax for cerebral ischemia. That conclusion is specific to the agency’s review and does not mean the reports do not exist. A later HHS interim enforcement-discretion policy covering specified forms under conditions is not FDA approval or proof of benefit. See the profile’s policy context.34
What matters in recovery now?
Recovery differs by stroke, timing and the person’s goals. A stroke or rehabilitation team can help assess movement, communication, daily activities and other needs, and discuss the available evidence with the person and their family. The short brain-scan studies in healthy volunteers ask another question entirely: see what those scans measured. For a broader route into questions about movement and recovery, explore joints and recovery.8
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Effectiveness of semax in acute period of hemispheric ischemic strokeZhurnal Nevrologii i Psikhiatrii / PubMed · Comparative clinical report; Russian-language article and English abstract; 1997
- The efficacy of semax in the treatment of patients at different stages of ischemic strokeZhurnal Nevrologii i Psikhiatrii / PubMed · Primary clinical report; English abstract reviewed
- FDA Pharmacy Compounding Advisory Committee Semax briefingU.S. Food and Drug Administration · Regulator briefing
- HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug SubstancesU.S. Department of Health and Human Services · Policy PDF; Appendix A/B conditions and scope
- Stroke symptoms and warning signsAmerican Stroke Association · Emergency symptom guidance
- Symptoms of a strokeNHS · Public-health emergency guidance
- 112: the EU emergency phone numberEuropean Commission · Government emergency-number guidance
- Stroke rehabilitationAmerican Stroke Association · Patient rehabilitation overview